ADAM17 peptide (Aminoterminal end catalytic domain) (ab41216)

Product Name 

ADAM17 peptide (Aminoterminal end catalytic domain)

Product type 

Proteins and Peptides

Peptide 

Synthetic peptide ADAM17.


This peptide was used as an immunogen for ab28233 - ADAM17 antibody - Amino end of catalytic domain.

Specificity 

We have a range of domain specific antibodies for this target. For a full list please see all ADAM17 antibodies

Tested applications 
(see key)

ELISA, WB

Application notes 
(see key)

Recommended dilutions
ELISA: Use at an assay dependent dilution. WB: Use at an assay dependent dilution. This peptide can be used with studies using ab28233. Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.

Research areas 

Cancer >> Cancer Metabolism >> Response to hypoxia
Cell Biology >> Proteolysis / Ubiquitin >> Proteolytic enzymes >> Metalloprotease >> ADAMs
Cancer >> Signal transduction >> Other
Cancer >> Invasion/microenvironment >> ECM >> Extracellular matrix >> ADAM protein family
Stem Cells >> Signaling Pathways >> Notch >> Secreted
Signal Transduction >> Adapters >> Transmembrane
Neuroscience >> Neurology process >> Neurodegenerative disease >> Alzheimer's disease >> Other

Relevance 

ADAM17, also known as TNF alpha Convertase, or TACE, was first cloned from human epithelial cells. The ADAMs proteins are structurally similar, with a signal sequence, metalloprotease domain (inactive in some ADAMs), disintegrin domain, cystein rich domain, EGF like repeat, type I transmembrane and Cytoplasmic domain. A member of the metalloproteinase family containing disintegrin like domains (ADAMs), ADAM17 is known to process the TNF alpha trimer from the membrane attached precursor to the soluble form. ADAM17 contains the canonical HExxHxxxxxH zinc metalloproteinase motif, and has been shown to be proteolytically active, cleaving TNF precursor as well as TNF p75 receptor, myeloid precursor protein, amyloid plaque protein, L selectin and TGF alpha, making ADAM17 a "sheddase". ADAM17 contains a cleavage site for prohormone convertases (furin), and the majority of ADAM17 is secreted as activated enzyme, cleaved at the furin site. ADAM17 is known to associate with MAD2 via the Cytoplasmic domain, implying cellular regulation pathways. ADAM17 is expressed in a wide range of cells in culture. Three human ADAM17 sequences encode proteins with different cytoplasmic domains, as is the case for other ADAMs proteases. The 824 amino acid sequence encodes a 92,960 Dalton protein, the 807 AA sequence 91,003 Dalton, and the 694 AA sequence 78,543 Dalton predicted MW. Glycosylation and other post translational modifications increase the apparent molecular weight on PAGE gels. Mouse and rat ADAM17 sequences are both 827 AA, predicting 93,073 and 93,017 Dalton proteins, respectively. Reports have shown that ADAM17 expression in human breast tumor samples is an indicator of poor prognosis.

Purity 

>95% by SDS-PAGE

Storage buffer 

Preservative: None
Constituents: 0.001% Tween 20, 30mM HEPES, 2mM EDTA, 150mM Sodium chloride, pH 6.75

Form 

Liquid

Concentration 

1.000 mg/ml

Storage instructions 

Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Customer reviews (feedback) regarding ADAM17 peptide (Aminoterminal end catalytic domain)

Customer FAQs regarding ADAM17 peptide (Aminoterminal end catalytic domain)

Protocols for ADAM17 peptide (Aminoterminal end catalytic domain)

Price and availability of products related to ADAM17 peptide (Aminoterminal end catalytic domain)

ADAM17 peptide (Aminoterminal end catalytic domain) - related products: